<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016626</url>
  </required_header>
  <id_info>
    <org_study_id>CKD-123HPS08E</org_study_id>
    <secondary_id>123HPS08E</secondary_id>
    <nct_id>NCT01016626</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetic Characteristics of CKD-4101 (Mycophenolate Mofetil) Tablet</brief_title>
  <official_title>Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of CKD-4101 Tablet, in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and tolerance by comparing pharmacokinetic&#xD;
      characteristics between the CKD-4101 tablet and Mycophenolate mofetil capsule when&#xD;
      administered alone to healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy volunteers are administrated single-dose over the period I and II (Crossover) of&#xD;
      CKD-4101 1000mg and Mycophenolate mofetil capsule 1000mg.&#xD;
&#xD;
      Every time before and after each medication, PK parameters and safety of CKD-4101 tablet and&#xD;
      Mycophenolate mofetil capsule is performed using a blood sample and conducting some tests&#xD;
      respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetics of CKD-4101 tablet and Mycophenolate Mofetil capsule.</measure>
    <time_frame>0-48 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of CKD-4101 tablet and Mycophenolate Mofetil capsule from vital signs, physical exam, ECG, laboratory test, adverse event and so on.</measure>
    <time_frame>0-48 hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CKD-4101 tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate Mofetil capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-4101 tablet</intervention_name>
    <description>CKD-4101 tablet 1000 mg&#xD;
500mg/tablet, PO, 2 tablet once daily for D1 and D8(crossover)</description>
    <arm_group_label>CKD-4101 tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil capsule</intervention_name>
    <description>Mycophenolate Mofetil capsule 1000 mg&#xD;
250mg/capsule, PO, 4 capsule once daily for D1 and D8(crossover)</description>
    <arm_group_label>Mycophenolate Mofetil capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 20 aged and 45 aged in healthy males&#xD;
&#xD;
          -  Weight more than 45 kg, IBW ± 20% within the range&#xD;
&#xD;
               -  Ideal body weight = (Height cm - 100) x 0.9&#xD;
&#xD;
          -  Agreement with written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has symptoms of acute disease within 28 days of starting administration of&#xD;
             investigational drug&#xD;
&#xD;
          -  Subject with known for history(such as inflammatory gastrointestinal disease, gastric&#xD;
             or duodenal ulcer, liver diseases and so on) which affect the ADME of drug&#xD;
&#xD;
          -  Clinically significant, active gastrointestinal system, cardiovascular system,&#xD;
             pulmonary system, renal system, Blood system, digestive system, central nervous&#xD;
             system, mental disease or malignancy disease.&#xD;
&#xD;
          -  Inadequate subject by medical examination(medical history, physical examination,ECG,&#xD;
             laboratory test) within 28 days of starting administration of investigational drug&#xD;
&#xD;
          -  Inadequate result of laboratory test&#xD;
&#xD;
               -  AST or ALT &gt; 1.25 x upper limit of normal range&#xD;
&#xD;
               -  Total bilirubin &gt; 1.25 x upper limit of normal range&#xD;
&#xD;
               -  Abnormal level of WBC, Platelet, Hemoglobin WBC &lt; 3.5 x 1000/µL PLT &lt; 100 x&#xD;
                  1000/µL Hemoglobin &lt; 11g/dL&#xD;
&#xD;
          -  Clinically significant allergic disease(Except for mild allergic rhinitis seems to be&#xD;
             not need for medication)&#xD;
&#xD;
          -  HGPRT(Hypoxanthine-guanine phosphoribosyl-transferase)deficiency patient such as&#xD;
             Lesch-Nyhan syndrome and kelley-Seegmiller syndrome&#xD;
&#xD;
          -  Severe renal dysfunction: Creatinine clearance less than 50ml/min by cockroft-Gault&#xD;
             calculation&#xD;
&#xD;
          -  Subject with known for hypersensitivity reaction to mycophenolic acid and&#xD;
             mycophenolate mofetil analog&#xD;
&#xD;
          -  Previously participated in other trial within 60 days&#xD;
&#xD;
          -  Treatment with dug-medicated induction/inhibition metabolic enzyme such as&#xD;
             barbiturates within 1month or with may affect the clinical trial within 10 days&#xD;
&#xD;
          -  Unusual diet may affect the ADME of drug&#xD;
&#xD;
          -  Not able to taking the institutional standard meal&#xD;
&#xD;
          -  Previously make whole blood donation within 60 days or component blood donation within&#xD;
             20 days&#xD;
&#xD;
          -  Continued to be taking caffeine (caffeine &gt; 5 cup/day), drinking(alcohol &gt; 30 g/day)&#xD;
             and during clinical trials can not be drunk or severe heavy smoker (cigarette &gt; 1/2&#xD;
             pack per day)&#xD;
&#xD;
          -  An impossible one who participates in clinical trial by investigator's decision&#xD;
             including for reason of laboratory test result&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Young Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>jypark21@korea.ac.kr</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>November 18, 2009</study_first_submitted>
  <study_first_submitted_qc>November 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2009</study_first_posted>
  <last_update_submitted>November 18, 2009</last_update_submitted>
  <last_update_submitted_qc>November 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ji Hye Lee</name_title>
    <organization>Chong Kun Dang Pharmaceutical</organization>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Mycophenolate Mofetil</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

